Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from ProKidney ( (PROK) ).
On July 1, 2025, ProKidney Corp. completed its transition from being incorporated in the Cayman Islands to Delaware, following shareholder approval at its Annual General Meeting on May 29, 2025. This change, effective immediately, involved the automatic conversion of Class A and Class B ordinary shares into common stock under the new Delaware corporation, with no anticipated impact on daily operations. The company’s stock will continue trading under the symbol ‘PROK’ on Nasdaq, with a new CUSIP number for its Class A common stock.
The most recent analyst rating on (PROK) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Underperform.
ProKidney’s stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
ProKidney Corp. is a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). Founded in 2015, the company is pioneering treatments through innovations in cellular therapy, with its lead product candidate, rilparencel (REACT®), being evaluated for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
Average Trading Volume: 1,176,335
Technical Sentiment Signal: Sell
Current Market Cap: $195.7M
Find detailed analytics on PROK stock on TipRanks’ Stock Analysis page.